Synonyms: POL-6326 | POL6326
Compound class:
Peptide or derivative
Comment: Balixafortide (POL6326) is an orally bioavailable cyclic peptide antagonist of the CXC chemokine receptor 4 (CXCR4). The CXCR4/SDF-1 axis regulates function and trafficking of immune cells. Balixafortid blocks interaction of the receptor with its ligand CXCL12 (SDF-1) [1]. Disrupting the SDF-1/CXCR4 interaction is ubeing exploited for mobilisation and harvesting of peripheral blood HSCs for transplant procedures, and in cancer therapy for antimetastatic activity (by dislodging stem cells from the bone marrow).
The peptide structure is cyclo[L-alanyl-L-cysteinyl-L-seryl-L-alanyl-D-prolyl-(2S)-2,4-diaminobutanoyl-L-arginyl-L-tyrosyl-L-cysteinyl-L-tyrosyl-L-glutaminyl-L-lysyl-D-prolyl-L-prolyl-L-tyrosyl-L-histidyl](2-9)-disulfide (from the INN record for balixafortide). |
No information available. |
Summary of Clinical Use |
Balixafortide (POL6326) was advanced to clinical evaluations in solid tumours and hematoogical malignancies. It had reached Phase 3 investigation (in combination with eribulin chemotherapy) for potential to treat advanced/heavily pre-treated HER2-negative breast cancer, but failed when the co-primary endpoint of the study (objective response rate) was not met. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT01837095 | Dose Escalation of POL6326 in Combination With Eribulin in Patients With Metastatic Breast Cancer | Phase 1 Interventional | Polyphor Ltd. | 3 | |
NCT01105403 | Exploratory Study on POL6326 in Stem Cell Mobilization | Phase 2 Interventional | Polyphor Ltd. | ||
NCT03786094 | Pivotal Study in HER2 Negative, Locally Recurrent or Metastatic Breast Cancer | Phase 3 Interventional | Polyphor Ltd. |